💇 Finasteride DHT Blockade Hair Growth Simulator

Androgenic Alopecia — DHT-Driven Follicle Miniaturization

Placeholder lead: DHT binds receptors, shrinking susceptible follicles over years.

• Dermal papilla: Type II 5-AR location (placeholder short caption)
• ~5x testosterone: DHT receptor affinity (placeholder short caption)
• ~50%: Affected men by 50 (placeholder short caption)
• Years: Miniaturization span (placeholder short caption)

How DHT shrinks follicles

Placeholder body text: DHT signaling shortens anagen phase, follicles shrink cycle by cycle.

Genetic susceptibility factors

Placeholder body text: androgen receptor gene variants set individual sensitivity levels.

Placeholder highlight: miniaturization is gradual and reversible early on.

Finasteride Inhibits 5α-Reductase Type II

Placeholder lead: finasteride binds the enzyme active site, blocking its function.

• 5-AR Type II: Target enzyme (placeholder short caption)
• 1 mg/day: Standard oral dose (placeholder short caption)
• Competitive: Inhibition mechanism (placeholder short caption)
• Weeks: Onset of action (placeholder short caption)

Enzyme active-site blockade

Placeholder body text: finasteride forms a stable complex occupying the catalytic pocket.

Dose adherence matters

Placeholder body text: consistent daily dosing sustains enzyme inhibition levels.

Placeholder highlight: missed doses let enzyme activity partially rebound.

Scalp DHT Levels Drop Roughly 70%

Placeholder lead: blocked conversion sharply lowers local scalp DHT concentration.

• ~70%: Scalp DHT reduction (placeholder short caption)
• ~70%: Serum DHT reduction (placeholder short caption)
• Slightly up: Testosterone level (placeholder short caption)
• ~1 month: Steady state reached (placeholder short caption)

Where the blocked testosterone goes

Placeholder body text: unconverted testosterone remains available, DHT pathway suppressed.

Follicular DHT exposure falls

Placeholder body text: lower local DHT reduces androgen receptor signaling at follicles.

Placeholder highlight: type I 5-AR still produces some residual DHT.

Miniaturization Halts, Regrowth Begins

Placeholder lead: surviving follicles re-enter longer anagen growth phases.

• ~Month 2–4: Shedding phase (placeholder short caption)
• ~Month 4–6: Visible thickening (placeholder short caption)
• Increases: Anagen phase length (placeholder short caption)
• Unchanged: Follicle count (placeholder short caption)

Recovery curve over months

Placeholder body text: thickening progresses gradually, plateauing near a year.

Temporary shed before regrowth

Placeholder body text: early synchronized shedding often precedes visible improvement.

Placeholder highlight: fully miniaturized follicles rarely fully recover.

Density Stabilizes — Reversible if Stopped

Placeholder lead: sustained therapy maintains gains; stopping resumes miniaturization.

• 6–12 mo: Plateau reached (placeholder short caption)
• Majority: Continued users improved (placeholder short caption)
• Reverses: Effect after stopping (placeholder short caption)
• ~12 months: Reversal timeframe (placeholder short caption)

Maintaining long-term gains

Placeholder body text: ongoing daily therapy is required to preserve density gains.

What happens if therapy stops

Placeholder body text: DHT rebounds and miniaturization resumes within months.

Placeholder highlight: benefit is maintenance, not a permanent cure.